← back to search

Abhishek Abhishek

University of Nottingham · GB
Area of research
Rheumatology · Nephrology
Research interest
Research interests include Gout, Hyperuricemia, Uric Acid, Rheumatoid Arthritis Research and Therapies, Osteoarthritis Treatment and Mechanisms, and Spondyloarthritis Studies and Treatments.
h-index
40
citations
7,307
works
485
NIH funding
primary concept
Medicine
email

Recent publications

Treat-to-Target Urate-Lowering Treatment and Cardiovascular Outcomes in Patients With Gout
JAMA Internal Medicine 2026cited by 7position: lastdoi
The 2025 British Society for Rheumatology guideline for the prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs.
2026cited by 2position: contributordoi
Reply.
2026cited by 0position: contributordoi
Cost-effectiveness of risk-stratified blood test monitoring strategies for adults with inflammatory conditions.
2026cited by 0position: contributordoi
The development of a risk threshold to aid risk stratified approach to monitoring for haematological, hepatic and/or renal adverse drug reactions during established cs DMARD treatment for systemic autoimmune rheumatic diseases: a RAND/UCLA Appropriateness Method consensus study.
2026cited by 0position: contributordoi
Short-Term Risk of Cardiovascular Events in People Newly Diagnosed With Gout.
2025cited by 18position: contributordoi
Comparative Cardiovascular Safety of Nonsteroidal Anti‐Inflammatory Drug Versus Colchicine Use When Initiating Urate‐Lowering Therapy Among Patients With Gout: Target Trial Emulations
Arthritis & Rheumatology 2025cited by 8position: middledoi
Incidence of Side Effects Associated With Acetaminophen in People Aged 65 Years or More: A Prospective Cohort Study Using Data From the Clinical Practice Research Datalink.
2025cited by 8position: contributordoi
Comparative Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drug Versus Colchicine Use When Initiating Urate-Lowering Therapy Among Patients With Gout: Target Trial Emulations.
2025cited by 6position: contributordoi
Effects of Pharmacologic and Nonpharmacologic Interventions for the Management of Sleep Problems in People With Fibromyalgia: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
2025cited by 4position: contributordoi
Gout on the acute medical take
Clinical Medicine 2025cited by 4position: contributordoi
Uptake and safety of pneumococcal vaccination in adults with immune-mediated inflammatory diseases: a UK wide observational study.
2025cited by 3position: contributordoi
Development and internal-external cross-validation of a patient-reported definition for acute calcium pyrophosphate crystal arthritis.
2025cited by 1position: contributordoi
Effects of pharmacological and non-pharmacological interventions for the management of sleep problems in people with fibromyalgia: a multi-methods evidence synthesis.
2025cited by 1position: contributordoi
Reply.
2025cited by 0position: contributordoi
Association of patient- and hospital-level predictors with patterns of initial treatment in patients with rheumatoid arthritis: findings from a national cohort study.
2025cited by 0position: contributordoi
Variation in blood test monitoring practices for patients treated with conventional and biologic DMARDs.
2025cited by 0position: contributordoi
Genetic variants associated with gout identified through a genome-wide study in the UK biobank (N = 150 542).
2025cited by 0position: contributordoi
The impact of pausing Bruton Tyrosine Kinase inhibitor (BTKi) therapy versus continued therapy on vaccination immune response in patients with chronic lymphocytic leukaemia: the IMPROVE RCT
2025cited by 0position: contributor
Tradition Versus Innovation: Conventional Radiography and Ultrasound in Calcium Pyrophosphate Deposition Identification. Instructions for Use.
2025cited by 0position: contributordoi
Temporary 2-week suspension of methotrexate treatment to enhance COVID-19 vaccine response in people with immune-mediated inflammatory diseases: the VROOM RCT
2025cited by 0position: contributor
Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study)
Efficacy and Mechanism Evaluation 2025cited by 0position: contributordoi
Temporary 2-week suspension of methotrexate treatment to enhance COVID-19 vaccine response in people with immune-mediated inflammatory diseases: the VROOM RCT
Efficacy and Mechanism Evaluation 2025cited by 0position: contributordoi
Novel Genetic Variants Associated with Gout Identified Through a Genome-Wide Study in the UK Biobank (N = 150,542)
2025cited by 0position: contributordoi
The impact of pausing Bruton Tyrosine Kinase inhibitor (BTKi) therapy versus continued therapy on vaccination immune response in patients with chronic lymphocytic leukaemia: the IMPROVE RCT
Efficacy and Mechanism Evaluation 2025cited by 0position: contributordoi
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial
Efficacy and Mechanism Evaluation 2025cited by 0position: contributordoi
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial
Efficacy and Mechanism Evaluation 2025cited by 0position: contributordoi
A genome-wide association analysis reveals new pathogenic pathways in gout
Nature Genetics 2024cited by 79position: middledoi
The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout
Nature Reviews Rheumatology 2024cited by 33position: middledoi
Features Associated With Different Inflammatory Phenotypes of Calcium Pyrophosphate Deposition Disease: A Study Using Data From the International American College of Rheumatology/EULAR Calcium Pyrophosphate Deposition Classification Criteria Cohort
Arthritis & Rheumatology 2024cited by 14position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

· 49 papers (2019–2026) · 17 papers (2022–2026)Christian Mallen · Keele University16 papers (2019–2026) · 10 papers (2022–2025)Michael Doherty · Baylor Scott & White Health9 papers (2019–2025)Nicola Dalbeth · Auckland University of Technology9 papers (2020–2025)Tim Card · Nottingham University Hospitals NHS Trust7 papers (2022–2026)Guruprasad P. Aithal · NIHR Nottingham Hearing Biomedical Research Unit7 papers (2022–2026)Matthew J Grainge · University of Nottingham5 papers (2022–2025)James Galloway · King's College London5 papers (2023–2026)Emilio Filippucci · Carlo Forlanini Hospital5 papers (2022–2024) · 5 papers (2023–2026) · 5 papers (2021–2024)Michael Doherty · Nottingham Biomedical Research Centre5 papers (2017–2022)Hywel C Williams · University of Nottingham5 papers (2022–2026)Sara K. Tedeschi · Brigham and Women's Hospital5 papers (2020–2022)Christopher P. Fox · Mayo Clinic in Florida5 papers (2022–2026)Ken Cai · University of Auckland4 papers (2020–2021) · 4 papers (2020–2021)Silvia Sirotti · University of Milan4 papers (2024–2025)